380 related articles for article (PubMed ID: 31482461)
1. Upconversion Nanoparticle-Based Strategy for Crossing the Blood-Brain Barrier to Treat the Central Nervous System Disease.
Fu L; Chung R; Shi B
Methods Mol Biol; 2019; 2054():263-282. PubMed ID: 31482461
[TBL] [Abstract][Full Text] [Related]
2. Aspect Ratio of PEGylated Upconversion Nanocrystals Affects the Cellular Uptake In Vitro and In Vivo.
Fu L; Shi B; Wen S; Morsch M; Wang G; Zhou Z; Mi C; Sadraeian M; Lin G; Lu Y; Jin D; Chung R
Acta Biomater; 2022 Jul; 147():403-413. PubMed ID: 35605956
[TBL] [Abstract][Full Text] [Related]
3. Nootropic nanocomplex with enhanced blood-brain barrier permeability for treatment of traumatic brain injury-associated neurodegeneration.
Park J; Choi E; Shin S; Lim S; Kim D; Baek S; Lee KP; Lee JJ; Lee BH; Kim B; Jeong K; Baik JH; Kim YK; Kim S
J Control Release; 2018 Aug; 284():152-159. PubMed ID: 29913220
[TBL] [Abstract][Full Text] [Related]
4. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
Zhao X; Ye Y; Ge S; Sun P; Yu P
Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
[TBL] [Abstract][Full Text] [Related]
5. A versatile upconversion surface evaluation platform for bio-nano surface selection for the nervous system.
Fu L; Morsch M; Shi B; Wang G; Lee A; Radford R; Lu Y; Jin D; Chung R
Nanoscale; 2017 Sep; 9(36):13683-13692. PubMed ID: 28876356
[TBL] [Abstract][Full Text] [Related]
6. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
[TBL] [Abstract][Full Text] [Related]
7. Salvaging brain ischemia by increasing neuroprotectant uptake via nanoagonist mediated blood brain barrier permeability enhancement.
Zheng S; Bai YY; Liu Y; Gao X; Li Y; Changyi Y; Wang Y; Chang D; Ju S; Li C
Biomaterials; 2015 Oct; 66():9-20. PubMed ID: 26188608
[TBL] [Abstract][Full Text] [Related]
8. The Role of Lipid Nanoparticles and its Surface Modification in Reaching the Brain: An Approach for Neurodegenerative Diseases Treatment.
Hernando S; Pedraz JL; Igartua M; Hernandez RM
Curr Drug Deliv; 2018; 15(9):1218-1220. PubMed ID: 29745334
[No Abstract] [Full Text] [Related]
9. Targeted delivery of nano-therapeutics for major disorders of the central nervous system.
Gao H; Pang Z; Jiang X
Pharm Res; 2013 Oct; 30(10):2485-98. PubMed ID: 23797465
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain.
Tian XH; Wei F; Wang TX; Wang P; Lin XN; Wang J; Wang D; Ren L
Int J Nanomedicine; 2012; 7():1031-41. PubMed ID: 22403486
[TBL] [Abstract][Full Text] [Related]
11. The role of non-endothelial cells on the penetration of nanoparticles through the blood brain barrier.
Moura RP; Almeida A; Sarmento B
Prog Neurobiol; 2017 Dec; 159():39-49. PubMed ID: 28899762
[TBL] [Abstract][Full Text] [Related]
12. Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Wang N; Sun P; Lv M; Tong G; Jin X; Zhu X
Biomater Sci; 2017 May; 5(5):1041-1050. PubMed ID: 28378865
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
Pinheiro RGR; Coutinho AJ; Pinheiro M; Neves AR
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769082
[TBL] [Abstract][Full Text] [Related]
14. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
[TBL] [Abstract][Full Text] [Related]
16. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
17. Transportation of Single-Domain Antibodies through the Blood-Brain Barrier.
Ruiz-López E; Schuhmacher AJ
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439797
[TBL] [Abstract][Full Text] [Related]
18. Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases.
Anthony DP; Hegde M; Shetty SS; Rafic T; Mutalik S; Rao BSS
Life Sci; 2021 Jun; 274():119326. PubMed ID: 33711385
[TBL] [Abstract][Full Text] [Related]
19. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier.
Sharma G; Sharma AR; Lee SS; Bhattacharya M; Nam JS; Chakraborty C
Int J Pharm; 2019 Mar; 559():360-372. PubMed ID: 30721725
[TBL] [Abstract][Full Text] [Related]
20. Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges.
Zhang W; Mehta A; Tong Z; Esser L; Voelcker NH
Adv Sci (Weinh); 2021 May; 8(10):2003937. PubMed ID: 34026447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
